Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis

Journal of Clinical Pharmacology

Volumn 38, Issue 4, 1998, Pages 347-356

  Marino, Maria R ^a   Langenbacher, Kathleen M ^b   Raymond, Ralph H ^a   Ford, Neville F ^a   Lasseter, Kenneth C ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Clinical Pharmacology Associates Miami   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; IRBESARTAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; LIVER CIRRHOSIS; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS;

EID: 0031946984     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04434.x     Document Type: Article

References (36)

1. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-834.
2. 1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994;251:143-150.
3. Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD: Angiotensin II receptors and functional correlates. Am J Hypertens 1992;5(suppl):221S-225S.
4. Bernstein KE, Berk BC: The biology of angiotensin II receptors. Am J Kidney Dis 1993;22:745-754.
5. iα3 (abstract). J Hypertens 1996;14(suppl): S77.
6. Hagmann M, Burnier M, Nussberger J, Leenhardt AF, Brouard R, Waeber B, et al: Natriuretic and hormonal effects of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in normotensive volunteers (abstract). Am J Hypertens 1994;7:13A.
7. Martinez F, Schmitt F, Savoiu C, Leenhardt AF, Brouard R, Peronnet P, et al: Effect of SR 47436 (BMS 186295) on renal hemodynamics and on glomerular permselectivity in healthy humans (abstract). J Am Soc Nephrol 1994;5:607.
8. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, et al: Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995;25:602-609.
9. Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R: Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295) (abstract). J Hypertens 1994;12:S92.
10. McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL: Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. J Cardiovasc Pharmacol 1996; 28:101-106.
11. 1 receptor antagonist irbesartan in hypertension. Hypertension 1995;25:22-29.
12. Pool JL, Guthrie RM, Littlejohn T, Raskin P, Shepherd AMM, Weber MA, et al: The antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension (abstract). Am J Hypertens 1996;9:152A.
13. Marino MR, Langenbacher KM, Raymond RH, Whigan D, Ford NF: Pharmacokinetics and antihypertensive effects of irbesartan (an AII receptor antagonist) in subjects with hypertension (abstract). J Hypertens 1996;14:S348.
14. Necciari J, Denolle T, Le Coz F, Donazollo Y, Pastor G, Sissmann J: Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man (abstract). J Hypertens 1994;12:88.
15. Eberhardt RT, Kevak RM, Kang PM, Frishman WH: Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 1993;33:1023-1038.
16. Gottlieb SS, Dickstein K, Fleck E, Kostis I, Levine TB, Lejemtel T, et al: Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-1609.
17. Lacourcière Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, et al: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-1393.
18. Vachharajani N, Chang S-Y, Shyu WC, Greene D, Barbhaiya R: Absolute bioavailability of irbesartan, an angiotensin II receptor antagonist, in man (abstract). Pharm Res 1995;12:S418.
19. Marino MR, Langenbacher KM, Ford NF, Uderman HD: Safety, tolerability, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects (abstract). Clin Pharmacol Ther 1997;61:207.
20. Perrier L, Bourrié M, Marti E, Tronquet G, Massé D, Berger Y, et al: In vitro N-glucuronidation of SR 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther 1994;271:91-99.
21. Vachharajani N, Shyu WC, Smith R, Chang S-Y, Greene D, Barbhaiya R: The effects of age and gender on the pharmacokinetics of irbesartan (abstract). Pharm Res 1995;12:S388.
22. Siegl PKS: Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist. J Hypertens 1993;11(suppl 3): S19-S22.
23. Triggle DJ: Anigotensin II receptor antagonism: losartan - sites and mechanisms of action. Clin Ther 1995;17:1005-1030.
24. Lo M-W, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-649.
25. Albers I, Hartmann H, Bircher J, Creutzfeldt W: Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989;24:269-276.
26. Kawaski S, Sugiyama Y, Iga T: Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. Clin Pharmacol Ther 1988; 44:217-224.
27. Chang SY, Whigan DB, Vachharajani N: High-performance liquid Chromatographic assays for the quantification of irbesartan in human plasma and urine. J Chromatogr B Biomed Sci Appl 1997;702:149-155.
28. Farmen RH, Muniak JF, Pittman KA: Management of pharmacokinetic data using HP-3357/mainframe IBM interfacing. Drug Information J 1987;21:141-153.
29. Locke CS: An exact confidence interval from untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm 1984;12:649-655.
30. Epstein M: The renin-angiotensin system in liver disease. In, Epstein M (ed.): The Kidney in Liver Disease. New York: Elsevier, 1983:353-373.
31. Rector WG Jr, Lewis FW, Adair OV, Robertson AD: Plasma renin activity in alcoholic liver disease. Am J Med 1992;92:485-493.
32. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-297.
33. Ogihara T, Nagano M, Mikami H, Higaki J, Kohara K, Azuma J, et al: Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994;16:74-86.
34. Muller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H: Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994;47:231-245.
35. Kang PM, Landau AJ, Eberhardt RT, Frishman WH: Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994;127:1388-1401.
36. Timmermans PBMWM, Smith RD: Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 1994;15(suppl D):79-87.